| Author (Corporate) | European Commission |
|---|---|
| Series Title | COM |
| Series Details | (2013) 495 final (10.7.13) |
| Publication Date | 10/07/2013 |
| Content Type | Policy-making |
|
In the context of the economic and financial crisis Europe is taking steps to find a path to sustainable growth. At the same time, Europe is faced with a series of important major challenges, such as climate change, finding sources of clean energy and improving the health and wellbeing of its citizens while containing the costs of healthcare. One of the aims of Horizon 2020, Europe's flagship programme for research and innovation, is to strengthen European industry by taking action to support research and innovation across a range of industrial sectors. In particular, Horizon 2020 encourages public-private partnerships in research and innovation to help tackle some of the key challenges Europe faces, including in the public health sector. The proposal for a public-private partnership builds on the Innovative Medicines Initiative Joint Undertaking (IMI JU) established under the 7th Research Framework Programme (‘FP7’) by Regulation (EC) No 73/2008 of the Council of 20 December 2007. IMI JU is a public-private partnership between the European Commission and the biopharmaceutical industry, and its objective is to improve the drug development process by supporting more efficient research and development cooperation among academia, small and medium enterprises (‘SMEs’) and the biopharmaceutical industry, in order to deliver better and safer medicines for patients. This proposal is in line with the Commission Communication 'Public-private partnerships in Horizon 2020: a powerful tool to deliver on innovation and growth in Europe'. |
|
| Source Link | http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=COM:2013:495:FIN |
| Related Links |
|
| Subject Categories | Culture, Education and Research |
| Countries / Regions | Europe |
